Population Pharmacokinetic Analysis of BMS‐986166, a Novel Selective Sphingosine‐1‐Phosphate‐1 Receptor Modulator, and Exposure‐Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants-Reference-Cited by-同舟云学术

Population Pharmacokinetic Analysis of BMS‐986166, a Novel Selective Sphingosine‐1‐Phosphate‐1 Receptor Modulator, and Exposure‐Response Assessment of Lymphocyte Counts and Heart Rate in Healthy Participants

Published:2020-10-08 Issue:1 Volume:10 Page:8-21
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Bihorel Sébastien¹,Singhal Shalabh²,Shevell Diane²,Sun Huadong³,Xie Jenny²,Basdeo Shenita²,Liu Ang²,Dutta Santanu²,Ludwig Elizabeth¹,Huang Hannah¹,Lin Kuan‐ju⁴,Fura Aberra²,Throup John²,Girgis Ihab G.²

Affiliation:

1. Cognigen Corporation a SimulationsPlus Company Buffalo New York USA

2. Bristol Myers Squibb Princeton New Jersey USA

3. Previously employed at Bristol Myers Squibb Princeton New Jersey USA

4. Previously employed at Cognigen Corporation, a SimulationPlus Company Buffalo New York USA

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.878

Reference39 articles.

1. Physiological and pathological actions of sphingosine 1-phosphate

2. Identification and Preclinical Pharmacology of ((1R,3S)-1-Amino-3-((S)-6-(2-methoxyphenethyl)-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol (BMS-986166): A Differentiated Sphingosine-1-phosphate Receptor 1 (S1P1) Modulator Advanced into Clinical Trials

3. Modulators of Sphingosine-1-phosphate Pathway Biology: Recent Advances of Sphingosine-1-phosphate Receptor 1 (S1P1) Agonists and Future Perspectives

4. Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis

5. The sphingosine 1-phosphate receptor modulator fingolimod as a therapeutic agent: Recent findings and new perspectives